scholarly article | Q13442814 |
P50 | author | Ruby Dizon | Q118382775 |
Marilyn E Crisostomo | Q118382777 | ||
Hazel Z Dytioco | Q118382778 | ||
Thelma M Laot | Q118382779 | ||
P2093 | author name string | Beatriz P Quiambao | |
Dirk E Teuwen | |||
P2860 | cites work | Is injecting a finger with rabies immunoglobulin dangerous? | Q36560046 |
Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey | Q39754170 | ||
The incurable wound revisited: progress in human rabies prevention? | Q40718615 | ||
A tale of two worlds: public health management decisions in human rabies prevention | Q43218201 | ||
Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model | Q47387628 | ||
A study of human rabies immune globulin manufactured by the Thai Red Cross | Q74586102 | ||
Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine | Q77429475 | ||
Rabies post-exposure prophylaxis in malnourished children exposed to suspect rabid animals | Q81223506 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | rabies immunoglobulin | Q4067112 |
Philippines | Q928 | ||
rabies | Q39222 | ||
post-exposure prophylaxis | Q1361206 | ||
P304 | page(s) | e243 | |
P577 | publication date | 2008-05-28 | |
P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
P1476 | title | Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab). | |
P478 | volume | 2 |
Q41495590 | An addition to treatment options for avian influenza A H5N1? |
Q90520682 | An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route |
Q38708817 | Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens |
Q33872166 | Bites from the same dog, different outcomes for two patients: a case report |
Q35065696 | Factors associated with delay in post-exposure prophylaxis in bitten people |
Q90137863 | Fatal outcomes following immunization errors as reported to the EudraVigilance: A case series |
Q57926583 | Human rabies post exposure prophylaxis in Bhutan, 2005–2008: Trends and risk factors |
Q38924824 | Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV. |
Q60191963 | Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003–2014 |
Q39374912 | Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines |
Q41495598 | Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study |
Q58093670 | Scoping decades of dog evidence: a scoping review of dog bite-related sequelae |
Q42228728 | Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice |
Q38997495 | Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab')2 fragments |
Q47222982 | Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biolog |
Q54107517 | [Rabies]. |
Q92455760 | mRNA: A Novel Avenue to Antibody Therapy? |